Cetrorelix: Uses, indications and precautions when using

Cetrorelix is ​​prepared in the form of acetate salt for injection, the active ingredient is cetrorelix acetate. It is used to prevent premature ovulation in the treatment of controlled ovarian stimulation.

Cetrorelix is ​​a synthetic decapitide with gonadotropin-releasing hormone (GnRH) antagonist activity used in women undergoing controlled ovarian stimulation. Cetrorelix is ​​often used in combination with other hormones (such as FSH and hCG). Cetrorelix works by blocking the release of the hormone LH which in turn helps prevent premature ovulation and gives the egg time to develop normally.

2.1. Indications Cetrorelix is ​​indicated for the prevention of premature ovulation in women undergoing controlled ovarian stimulation therapy followed by oocyte retrieval and assisted reproductive technology.
In clinical trials, Cetrorelix has been used with human menopausal gonadotropin (HMG), however, some experience with recombinant FSH (follicle-stimulating hormone) hormone has shown similar efficacy. on one's own.
2.2. Contraindications Cetrorelix is ​​contraindicated in patients with known hypersensitivity to cetrorelix acetate or structural analogues of gonadotropin-releasing hormone (GnRH), foreign peptide hormone or mannitol.
Pregnant women Lactating women Postmenopausal women Patients with moderate to severe renal and hepatic impairment.

The first injection of Cetrorelix should be done under the medical supervision of a physician in a place where treatment for a possible, false allergic or allergic reaction is immediately available. Subsequent injections may be self-administered, provided the patient has been instructed to recognize the signs and symptoms of hypersensitivity, the consequences of the reaction, and the need for immediate medical intervention.
Unless prescribed, Cetrorelix is ​​to be administered in the following manner:
The amount in 1 vial of powder for injection (0.25mg cetrorelix) is to be taken once daily, 24 hours apart in the morning or evening. After the first injection, the patient should be under medical supervision for 30 minutes to ensure there are no allergic or false allergic reactions to the injection. Cetrorelix is ​​for injection under the skin into the lower abdominal wall. Reactions at the injection site can be reduced by gently rubbing the injection site, limiting re-injection, and injecting at a slow rate to promote drug absorption. Morning use: Cetrorelix should be started on day 5 or 6 of ovarian stimulation (approximately 96 to 120 hours after ovarian stimulation) with recombinant gonadotropin or gonadotropinuria and continuously throughout the gonadotropin-treatment phase including on the day of ovulation. Evening use: Cetrorelix should be started on day 5 or 6 of ovarian stimulation (approximately 96 to 108 hours after ovarian stimulation) with recombinant or urinary gonadotropin and administered continuously during the gonadotropin treatment period until the evening immediately before the day of ovulation.

The most commonly reported side effect is injection site reactions such as erythema, pruritus and swelling, which are usually mild and transient.
Mild to moderate ovarian hyperstimulation syndrome (WHO class I or II) are commonly reported and they should be considered as an intrinsic risk of ovarian stimulation. egg. In contrast, severe ovarian hyperstimulation syndrome is uncommon. Reports of hypersensitivity reactions including allergic reactions, pseudo-allergic reactions (anaphylaxis) are uncommon. Gastrointestinal side effects such as nausea are uncommon.

5.1. Drug Interactions Laboratory studies have shown that Cetrorelix is ​​unlikely to interact with drugs that are metabolized by CYP450 (cytochrome P450) or are either glucuronic or conjugated in any way. However, even though there is no evidence of a drug interaction, the possibility of an interaction, especially with commonly used drugs, gonadotropins or products that can cause histamine release in susceptible individuals cannot be completely excluded. cold.
5.2. Note when using Cetrorelix Cetrorelix should only be mixed with the supplied solvent, using gentle rotation and avoiding strong shaking to form air bubbles. The solution after reconstitution must be clear and free of sediment. Do not use if solution is cloudy or not clear. The solution should be used immediately after reconstitution.
Each syringe, vial and needle are for single use only, cap the needles for safe disposal. Ask your doctor about the safe way to dispose of needles, vials, and syringes.
Special attention should be paid to women with symptoms and signs of allergy or a history of allergy susceptibility. The use of Cetrorelix is ​​not recommended for women with severe allergies.
As mentioned in the side effects section, ovarian hyperstimulation syndrome can occur during or after ovarian stimulation. Symptomatic treatment such as rest, intravenous electrolytes or colloids, and heparin therapy should be sought. Luteal phase support should follow the practice guidelines of the fertility medicine center.
Overdosage of Cetrorelix may prolong the duration of action of the drug, but it does not appear to be related to acute toxicity. Cetrorelix has no or negligible influence on the user's ability to drive and use machines.
Best before using Cetrorelix, you should consult your doctor, pharmacist for appropriate indications. Self-medication can have many potential risks, affecting the patient's health.

Vinmec International General Hospital is currently a high-quality medical examination address trusted by professionals and customers, as the hospital has achieved many successes in the examination and treatment of diseases from simple to complex. Therefore, in the process of taking Cetrorelix, if there are any problems, customers can contact the hospital for examination and appropriate indications from a team of highly qualified medical doctors and pharmacists.

Reference sources: Webmd.com, DailyMed, eMC